Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 15 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
PGBioclin from Limbourg, company number BE0747635715, closed financial year 2025 with a result of € 90,119 after tax. For that financial year PGBioclin recorded a gross margin of € 135,818 and equity of € 5,495. Compared with financial year 2024, the result moved from € 233,313 to € 90,119. The company is profitable. The buffer shrank hard: equity is 96 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on March 19, 2026.
€ 5,495
▼ 96% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 90,119
▼ 61% vs 2024
Profit after tax over the fiscal year.
€ 3,682
▼ 56% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 229,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 57,140
▼ 21% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 9,998
Loans from banks and other lenders, long and short.
€ 45
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 220,360 | € 248,492 | € 303,343 | € 135,818 | ▼ 55% |
| Profit after taxes | € 166,162 | € 188,472 | € 233,313 | € 90,119 | ▼ 61% |
| Equity | € 352,590 | € 61,062 | € 144,375 | € 5,495 | ▼ 96% |
| Total debts | € 33,197 | € 76,900 | € 34,634 | € 202,548 | ▲ € 167,914 |
| Cash | € 298,949 | € 3,418 | € 8,338 | € 3,682 | ▼ 56% |
| Retained profit | € 347,590 | € 56,062 | € 139,375 | € 495 | ▼ € 138,881 |
| Dividend | € 0 | € 480,000 | € 150,000 | € 229,000 | ▲ 53% |
| Bank debt | € 0 | € 0 | € 0 | € 9,998 | |
| Balance sheet total | € 385,787 | € 137,962 | € 179,010 | € 208,043 | ▲ 16% |
Key figures of PGBioclin, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PGBioclin?
What happened at PGBioclin in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 90,119 (▼ 61% vs 2024). Source: NBB ↗
- Paul Göbbels became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 166,162 profit in 2022 to € 90,119 profit in 2025.
Paid € 205,209 in corporate taxes since 2022.
Best year ever: 2024, with € 233,313 profit.
Paid out € 859,000 in dividends to the owners in total.
Management
Behind PGBioclin is Paul Göbbels.
Directors
According to the 2025 annual accounts
Paul Göbbels
Director
since 2020
Establishments
Establishment units
Physical locations of this company
Pirhettes 21
4834 Limbourg
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0747.635.715
- VAT number
- BE 0747.635.715
- Registered office
- Pirhettes 21, 4834 Limbourg
- Names & denominations
- PGBioclin
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 May 2020
- Peppol
- Not registered
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria